The treatment of advanced non-small cell lung cancer

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 4, 2005, Pages 287-291

  Spiro, Stephen G ^a,c   Silvestri, Gerard A ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Abnormal non small cell lung cancer; Chemotherapy; Elderly; Growth factors

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL;

CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; TIME; TUMOR GROWTH;

EID: 23044513852     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000166590.03042.56     Document Type: Review

References (28)

1. Spiro SG, Porter JC. Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166: 1166-1196.
2. Lui BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China: I. Retrospective proportional mortality study of one million deaths. BMJ 1998; 317:1411-1422.
3. van Tinteren H, Hoekstra O, Smit E, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS Multicentre Randomised Trial. Lancet 2002; 359:1388-1393.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
5. Cullen M, Billingham L, Woodroffe C, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-3194.
6. Smith I, O'Brien M, Talbot D, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19:1336-1343.
7. Cardenal F, Lopez-Cabrerizo M, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17:12-18.
8. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-631.
9. Schiller J, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92-98.
10. Fossella F, Pereira JR, von Pawel J, et al. Randomized multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003; 21:3016-3024.
11. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage NIB or IV non-small cell lung cancer: a phase III randomized study of London Lung Cancer Group. J Clin Oncol 2005; 23:142-153.
12. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial. J Clin Oncol 2003; 21:3207-3213.
13. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59:828-836. This is the largest study in advanced NSCLC to look at chemotherapy versus BSC.
14. Schiller JH. Platin or no platin? That is the question. J Clin Oncol 2003; 21:3009-3010.
15. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025-3034.
16. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomised study. J Clin Oncol 2002; 20:3578-3585.
17. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 2001; 357:1478-1484.
18. Sequist LV, Lynch TJ. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol 2003; 21:3186-3188.
19. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372.
20. Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2003; 95:341-343.
21. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European experts panel. Ann Oncol 2004; 15:419-426.
22. Wakeling AE, Guy SP, Woodburn JR, et al. ZD 1839(Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
23. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
24. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
25. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial. INTACT I. J Clin Oncol 2004; 22:777-784.
26. Green MR. Targeting targeted therapy. N Engl J Med 2004; 350:2191-2193.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. This article provides insights into the genetics of lung cancer and susceptibility for treatment.
28. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCICCTG) trial. 2004. Available at www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-00678,00.asp.